Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Adv Exp Med Biol. 2020;1231:13-21. doi: 10.1007/978-3-030-36667-4_2.
Within the tumor microenvironment, chemokines play a key role in immune cell trafficking regulation and immune landscape formulation. CCL3 or macrophage inflammatory protein-1α (MIP-1α), an important chemokine implicated in both immune surveillance and tolerance, has emerged as a prognostic biomarker in both solid and hematological malignancies. CCL3 exerts both antitumor and pro-tumor behavior which is context dependent highlighting the complexity of the underlying interrelated signaling cascades. Current CCL3-directed therapeutic approaches are investigational and further optimization is required to increase efficacy and minimize adverse events.
在肿瘤微环境中,趋化因子在免疫细胞迁移调节和免疫景观形成中发挥着关键作用。CCL3 或巨噬细胞炎症蛋白-1α(MIP-1α)是一种与免疫监视和耐受都有关的重要趋化因子,已成为实体瘤和血液恶性肿瘤的预后生物标志物。CCL3 具有抗肿瘤和促肿瘤双重行为,这取决于具体情况,突显了潜在相互关联的信号级联的复杂性。目前针对 CCL3 的治疗方法仍处于研究阶段,需要进一步优化以提高疗效并减少不良反应。